GlassScriptPhysician profile
Richard A Carter
NPI 1639155575
$5,552.94
in general payments reported to CMS, 2019-2025
37 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $474 · 2021: $1,257 · 2022: $1,332 · 2023: $737 · 2024: $694 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $954.50 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $512.22 | 2021-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $502.14 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $336.71 | 2020-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $268.37 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $265.85 | 2020-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $263.44 | 2019-2024 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Sunovion Pharmaceuticals INC. | $252.62 | 2021-2022 | |
| Pfizer INC. | $234.76 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $207.32 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $190.37 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $185.93 | 2021 | |
| Revance Therapeutics, INC. | $171.09 | 2024 | Daxxify |
| Amarin Pharma, INC. | $166.06 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.91 | 2019-2024 | Jardiance |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.